


In the Claims:

1-39. Cancelled

40. (Currently amended) A method of treating a tumor or cancer in a patient in need thereof comprising administering to said patient a pharmaceutical composition in oral, topical or systemic dosage form comprising an effective amount of a compound having the structure:



wherein R^1 is a methyl group and R^2 is an undecyl group or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, additive or excipient, wherein said tumor is selected from the group consisting of neurofibromatosis, tuberous sclerosis and hemangiomas and said cancer is selected from the group consisting of cervical, uterine, anal, ocular, stomach, colon, bladder, rectal, kidney, liver, pancreatic, lung, breast, ovarian, prostate, testicular, renal, brain/cns, head and neck, throat, esophageal, mouth, pharynx, larynx, Ewing's Sarcoma, Kaposi's Sarcoma, melanoma, basal cell carcinoma, small cell lung, squamous cell carcinoma, choriocarcinoma, rhabdomyosarcoma, angiosarcoma, Wilms Tumor, neuroblastoma and lymphoma.

41-49. Canceled.

50. (Previously presented) The method according to claim 40 wherein said tumor is selected from the group consisting of neurofibromatosis, tuberous sclerosis and hemangiomas and said cancer is basal cell carcinoma or squamous cell carcinoma.

51. (Previously presented) The method according to claim 40 wherein said cancer is selected from the group consisting of cervical, uterine, ovarian, anal, ocular, stomach,

S.N. 10/502,080

2

B40-002.Amendment Response 12-11

colon, bladder, rectal, liver, pancreatic, lung, breast, prostate, testis, renal, brain/cns, head and neck, throat, Ewing's Sarcoma, Kaposi's Sarcoma, basal cell carcinoma, squamous cell carcinoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, angiosarcoma, Wilms Tumor, neuroblastoma, mouth/pharynx, esophageal, larynx and lymphoma.

52. (Previously presented) The method according to claim 40 wherein said cancer is selected from the group consisting of cervical, anal, ocular, stomach, colon, bladder, rectal, liver, pancreatic, lung, breast, ovarian, prostate, testis, renal, brain/cns, head, neck and throat, mouth/pharynx, esophageal, larynx, kidney and lymphoma.

53. (Previously presented) The method according to claim 40 wherein said cancer is selected from the group consisting of Ewing's Sarcoma, Kaposi's Sarcoma, basal cell carcinoma, squamous cell carcinoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, angiosarcoma, hemangioendothelioma, Wilms Tumor, neuroblastoma, mouth/pharynx, esophageal, larynx, kidney and lymphoma.

54. (Previously presented) The method according to claim 40 wherein said cancer is selected from the group consisting of cervical, anal, testicular cancer, basal cell carcinoma and squamous cell carcinoma.

55. (Previously presented) The method according to claim 40 wherein said cancer is selected from the group consisting of stomach, colon, bladder, rectal, liver, pancreatic, lung, breast, brain/cns, head, neck, throat, mouth, pharynx, larynx, and esophageal.

56. (Previously presented) The method according to claim 40 wherein said cancer is selected from the group consisting of cervical, anal, ocular, stomach, colon, bladder, rectal, liver, pancreatic, lung, breast, renal, brain/cns and lymphoma.

57. Canceled.

58-66. (Canceled).

67. (Previously pending) The method according to claim 40 wherein said basal cell carcinoma or said squamous cell carcinoma is a cutaneous malignancy.

S.N. 10/502,080

3

B40-002.Amendment Response 12-11

68. (Previously pending) The method according to claim 40 wherein said cancer is basal cell carcinoma.

69. (Previously pending) The method according to claim 40 wherein said cancer is squamous cell carcinoma.

S.N. 10/502,080

4

B40-002.Amendment Response 12-11